Stockwatch: They shoot biotech horses don't they?
This article was originally published in Scrip
Executive Summary
This year, as well as last, the death of two horses at the recent UK Grand National race has led to a considerable amount of consternation amongst the horseracing, and even the general community. Interestingly, there are striking similarities between what has led to the death of so many UK biotechnology companies, and the changes that have led to the deaths at the Grand National.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.